A preclinical study by Burova and colleagues showed that REGN3767, a fully human antibody targeting LAG3, increased the efficacy of PD-1 blockade in a humanized mouse model and enhanced the production of pro-inflammatory cytokines by tumor-specific T lymphocytes [95]. Here, LAG3 is linked to neoplasm.